AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31589302 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibrio parahaemolyticus isolates with pirABVp genes
Number of subjects: 40
Study 31589302 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibrio parahaemolyticus isolates without pirAVp or pirABVp
Number of subjects: 40
Study 28934785 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive sacroiliac joint fusion (SIJF) using triangular titanium implants
Number of subjects: 103
Study 28934785 — intervention group
Group type: COMPARATOR
Intervention: Conservative management (CM)
Number of subjects: 103
Study 28934785 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive sacroiliac joint fusion (SIJF)
Number of subjects: 103
Study 25665520 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS (active TENS)
Number of subjects: 42
Study 25665520 — intervention group
Group type: COMPARATOR
Intervention: Control (sham TENS)
Number of subjects: 42
Study 23864098 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen, 5 mg/day
Number of subjects: 1884
Study 23864098 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1884
Study 21382868 — intervention group
Group type: EXPERIMENTAL
Intervention: E(dd)→T(dd)→CMF (dose-intensified chemotherapy)
Number of subjects: 733
Study 21382868 — intervention group
Group type: COMPARATOR
Intervention: EC→T (standard chemotherapy)
Number of subjects: 733
Study 21382868 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin
Number of subjects: 733
Study 21382868 — intervention group
Group type: COMPARATOR
Intervention: No darbepoetin
Number of subjects: 733
Study 21382868 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathological complete response (pCR)
Number of subjects: 733
Study 21382868 — intervention group
Group type: COMPARATOR
Intervention: No pathological complete response (pCR)
Number of subjects: 733
Study 19995249 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 2.5 mg/ml, 15 ml every three hours for 45 hours
Number of subjects: 43
Study 19995249 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 17853753 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at the five-zangshu
Number of subjects: 40
Study 17853753 — intervention group
Group type: COMPARATOR
Intervention: Premarin tablets (control)
Number of subjects: 40
Study 15206671 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 157
Study 15206671 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 157
Study 15206671 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 157
Study 15206671 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 157
Study 11486106 — intervention group
Group type: EXPERIMENTAL
Intervention: Prothrombotic disorders detected in patients
Number of subjects: 10
Study 11486106 — intervention group
Group type: EXPERIMENTAL
Intervention: Lupus anticoagulant
Number of subjects: 10
Study 11486106 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticardiolipin/anti‐beta(2)‐glycoprotein I antibodies
Number of subjects: 10
Study 9722109 — intervention group
Group type: EXPERIMENTAL
Intervention: Equipoise
Number of subjects: 0
Study 7833657 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose (30 mCi) radioactive iodine
Number of subjects: 200
Study 7833657 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose (50‐250 mCi) radioactive iodine
Number of subjects: 200
Study 7833657 — intervention group
Group type: COMPARATOR
Intervention: No postoperative treatment with radioactive iodine
Number of subjects: 200
Study 3259100 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 20
Study 3259100 — intervention group
Group type: COMPARATOR
Intervention: Methohexitone
Number of subjects: 20
Study 31820158 — intervention group
Group type: EXPERIMENTAL
Intervention: Hernia sac transection (TS)
Number of subjects: 70
Study 31820158 — intervention group
Group type: COMPARATOR
Intervention: Complete sac reduction (RS)
Number of subjects: 70
Study 31820158 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 70
Study 30921978 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency thermoablation of the Gasserian ganglion (Control)
Number of subjects: 40
Study 30921978 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency thermoablation of the peripheral branches of the trigeminal nerve (Study)
Number of subjects: 40
Study 28949844 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-genome sequencing (WGS) results disclosure
Number of subjects: 202
Study 28949844 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative interviews regarding WGS results
Number of subjects: 202
Study 26583660 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy (LCC)
Number of subjects: 85
Study 26583660 — intervention group
Group type: COMPARATOR
Intervention: Conservative watchful waiting (Control)
Number of subjects: 85
Study 24294742 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate plus Serophene (25 mg vaginally and 100-150 mg orally)
Number of subjects: 42
Study 21593403 — intervention group
Group type: COMPARATOR
Intervention: KP-1461 (400-3200 mg)
Number of subjects: 42
Study 21593403 — intervention group
Group type: COMPARATOR
Intervention: KP-1461 (3200 mg)
Number of subjects: 42
Study 21593403 — intervention group
Group type: EXPERIMENTAL
Intervention: KP-1461 (1600 mg)
Number of subjects: 42
Study 21593403 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 18284406 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 25 mg/day at night
Number of subjects: 43
Study 18284406 — intervention group
Group type: COMPARATOR
Intervention: Control group (no phosphodiesterase-5 inhibitors)
Number of subjects: 43
Study 18284406 — intervention group
Group type: COMPARATOR
Intervention: Comparison between sildenafil and control group
Number of subjects: 43
Study 17319450 — intervention group
Group type: EXPERIMENTAL
Intervention: CJC-1008
Number of subjects: 57
Study 17319450 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 12649818 — intervention group
Group type: EXPERIMENTAL
Intervention: Informal peer group experience
Number of subjects: 0
Study 12649818 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 15125329 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined vaccine (Twinrix: HAV 720 UE/HBV 20 micrograms)
Number of subjects: 73
Study 15125329 — intervention group
Group type: COMPARATOR
Intervention: Separate vaccines (Engerix B 20 micrograms/Havrix 720 UE)
Number of subjects: 73
Study 15125329 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined vaccine (Twinrix)
Number of subjects: 73
Study 15125329 — intervention group
Group type: COMPARATOR
Intervention: Separate vaccines (Engerix B/Havrix)
Number of subjects: 73
Study 15125329 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined vaccine (Twinrix) and Separate vaccines (Engerix B/Havrix)
Number of subjects: 73
Study 10471107 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 h HIV‐STD risk reduction behavioural skills building latex condom intervention
Number of subjects: 108
Study 10471107 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 h skills workshop focused on male polyurethane condoms
Number of subjects: 108
Study 10471107 — intervention group
Group type: COMPARATOR
Intervention: 3 h HIV education workshop
Number of subjects: 108
Study 7641922 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine insemination (IUI)
Number of subjects: 240
Study 7641922 — intervention group
Group type: COMPARATOR
Intervention: Fallopian sperm perfusion
Number of subjects: 240
Study 7641922 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine insemination (IUI) with clomiphene citrate (CC)
Number of subjects: 240
Study 7641922 — intervention group
Group type: COMPARATOR
Intervention: Fallopian sperm perfusion with clomiphene citrate (CC)
Number of subjects: 240
Study 7641922 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine insemination (IUI) with gonadotropins
Number of subjects: 240
Study 7641922 — intervention group
Group type: COMPARATOR
Intervention: Fallopian sperm perfusion with gonadotropins
Number of subjects: 240
Study 2787664 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2.8 mg kg‐1
Number of subjects: 40
Study 2787664 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopentone 5 mg kg‐1
Number of subjects: 40
Study 2787664 — intervention group
Group type: COMPARATOR
Intervention: Unmedicated controls (neonates delivered by uncomplicated vaginal delivery)
Number of subjects: 40
Study 59806 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing intervention (bi-weekly visits for two months)
Number of subjects: 9
Study 59806 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention after initial setup)
Number of subjects: 9
Study 31664046 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning model based on phase-diagram inspired parameters
Number of subjects: 600
Study 28414606 — intervention group
Group type: EXPERIMENTAL
Intervention: Topically applied undiluted heterologous serum
Number of subjects: 41
Study 28414606 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (0.9% NaCl) solution
Number of subjects: 41
Study 25595580 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg intravenous azithromycin, administered 15, 30, or 60 minutes before incision, infused over 1 hour
Number of subjects: 30
Study 25595580 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg intravenous azithromycin
Number of subjects: 30
Study 23334506 — intervention group
Group type: COMPARATOR
Intervention: HEC gel
Number of subjects: 1543
Study 23334506 — intervention group
Group type: COMPARATOR
Intervention: No-gel
Number of subjects: 1543
Study 21342392 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia (MM) presentation
Number of subjects: 61
Study 21342392 — intervention group
Group type: COMPARATOR
Intervention: Verbal consent
Number of subjects: 61
Study 21342392 — intervention group
Group type: COMPARATOR
Intervention: Pamphlet
Number of subjects: 61
Study 19760299 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear regression model
Number of subjects: 2003
Study 19760299 — intervention group
Group type: EXPERIMENTAL
Intervention: Probit regression model
Number of subjects: 2003
Study 19760299 — intervention group
Group type: COMPARATOR
Intervention: Single predictors (education or poverty alone)
Number of subjects: 2003
Study 17353316 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffusion and magnetization transfer (MT) techniques in CEC patients
Number of subjects: 35
Study 17353316 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffusion and magnetization transfer (MT) techniques in CD patients
Number of subjects: 35
Study 17353316 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 35
Study 15056118 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin-modified glass ionomer cement
Number of subjects: 971
Study 15056118 — intervention group
Group type: EXPERIMENTAL
Intervention: Compomer (polyacid-modified composite resin)
Number of subjects: 971
Study 15056118 — intervention group
Group type: EXPERIMENTAL
Intervention: Restorations with cavity conditioners
Number of subjects: 971
Study 15056118 — intervention group
Group type: EXPERIMENTAL
Intervention: Restorations without cavity conditioners
Number of subjects: 971
Study 15056118 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjacent unfilled surfaces
Number of subjects: 971
Study 15056118 — intervention group
Group type: COMPARATOR
Intervention: Overall study results
Number of subjects: 971
Study 11546903 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal baclofen (50 microgram)
Number of subjects: 21
Study 11546903 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intrathecal baclofen infusion (up to 12 months)
Number of subjects: 21
Study 9750976 — intervention group
Group type: EXPERIMENTAL
Intervention: Panic disorder on day 1
Number of subjects: 34
Study 9750976 — intervention group
Group type: EXPERIMENTAL
Intervention: Panic disorder on day 2
Number of subjects: 34
Study 9750976 — intervention group
Group type: COMPARATOR
Intervention: Social phobia
Number of subjects: 34
Study 9750976 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 34
Study 7810826 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% niclosamide lotion applied twice a week
Number of subjects: 350
Study 7810826 — intervention group
Group type: COMPARATOR
Intervention: Placebo lotion
Number of subjects: 350
Study 3415883 — intervention group
Group type: COMPARATOR
Intervention: 0.5% amethocaine with 0% dextrose
Number of subjects: 0
Study 3415883 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% amethocaine with 1.25% dextrose
Number of subjects: 0
Study 3415883 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% amethocaine with 2.5% dextrose
Number of subjects: 0
Study 3415883 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% amethocaine with 5% dextrose
Number of subjects: 0
Study 31829100 — intervention group
Group type: EXPERIMENTAL
Intervention: Enriched marine oil supplement
Number of subjects: 0
Study 31829100 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30813412 — intervention group
Group type: COMPARATOR
Intervention: Duodenal placebo and ileal placebo (DPIP)
Number of subjects: 14
Study 30813412 — intervention group
Group type: EXPERIMENTAL
Intervention: Duodenal tastants and ileal placebo (DTIP)
Number of subjects: 14
Study 30813412 — intervention group
Group type: EXPERIMENTAL
Intervention: Duodenal placebo and ileal tastants (DPIT)
Number of subjects: 14
Study 30813412 — intervention group
Group type: EXPERIMENTAL
Intervention: Duodenal tastants and ileal tastants (DTIT)
Number of subjects: 14
Study 28941607 — intervention group
Group type: EXPERIMENTAL
Intervention: Biventricular pacing (BiV)
Number of subjects: 120
Study 28941607 — intervention group
Group type: COMPARATOR
Intervention: Left ventricular pacing (LV)
Number of subjects: 120
Study 25467040 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon uterine stent
Number of subjects: 60
Study 25467040 — intervention group
Group type: COMPARATOR
Intervention: Control (no balloon uterine stent)
Number of subjects: 60
Study 23887151 — intervention group
Group type: COMPARATOR
Intervention: NMDA receptor blocker ketamine during retention sleep
Number of subjects: 0
Study 23887151 — intervention group
Group type: COMPARATOR
Intervention: AMPA receptor blocker caroverine during retention sleep
Number of subjects: 0
Study 23887151 — intervention group
Group type: EXPERIMENTAL
Intervention: NMDA receptor coagonist D-cycloserine (DCS) during retention sleep
Number of subjects: 0
Study 23887151 — intervention group
Group type: EXPERIMENTAL
Intervention: DCS during a wake interval
Number of subjects: 0
Study 21208675 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-glycemic load (GL) diet
Number of subjects: 79
Study 21208675 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 79
Study 19204565 — intervention group
Group type: EXPERIMENTAL
Intervention: Active stretching techniques
Number of subjects: 100
Study 19204565 — intervention group
Group type: COMPARATOR
Intervention: Straight leg raise (SLR) passive stretch
Number of subjects: 100
Study 19204565 — intervention group
Group type: EXPERIMENTAL
Intervention: PNF in the 90/90 active stretch
Number of subjects: 100
Study 17086502 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercially available ergonomic keyboard
Number of subjects: 68
Study 17086502 — intervention group
Group type: COMPARATOR
Intervention: Modified version of the ergonomic keyboard designed to reduce activation force, vibration, and key travel
Number of subjects: 68
Study 14977793 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 4 microg kg(‐1)
Number of subjects: 40
Study 14977793 — intervention group
Group type: COMPARATOR
Intervention: Midazolam 0.4 mg kg(‐1)
Number of subjects: 40
Study 14977793 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 11695354 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg once daily
Number of subjects: 220
Study 11695354 — intervention group
Group type: COMPARATOR
Intervention: Nizatidine 150 mg b.i.d.
Number of subjects: 220
Study 9159698 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical interpreters translated hepatitis B as rauk tlaam, literally 'liver disease'
Number of subjects: 34
Study 9159698 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of illnesses named after symptom complexes that include symptoms of acute and chronic hepatitis
Number of subjects: 34
Study 8203789 — intervention group
Group type: EXPERIMENTAL
Intervention: Daflon 500 mg (D500)
Number of subjects: 100
Study 8203789 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 100
Study 3580312 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-smoking health education during pregnancy
Number of subjects: 0
Study 3580312 — intervention group
Group type: COMPARATOR
Intervention: Control group (no anti-smoking health education)
Number of subjects: 0
Study 29614877 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-game group intervention
Number of subjects: 8
Study 27797279 — intervention group
Group type: EXPERIMENTAL
Intervention: Reference brand enteric‐coated capsules
Number of subjects: 24
Study 27797279 — intervention group
Group type: COMPARATOR
Intervention: Test generic enteric‐coated tablets
Number of subjects: 24
Study 26571421 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 73
Study 26571421 — intervention group
Group type: COMPARATOR
Intervention: Control (hyperuricemic)
Number of subjects: 73
Study 26571421 — intervention group
Group type: COMPARATOR
Intervention: Control (normouricemic)
Number of subjects: 73
Study 23416142 — intervention group
Group type: EXPERIMENTAL
Intervention: α‐lipoic acid (LA) supplementation (600 mg/day) for 28 days
Number of subjects: 16
Study 23416142 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal G6PD levels)
Number of subjects: 16
Study 21321256 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT)
Number of subjects: 193
Study 21321256 — intervention group
Group type: COMPARATOR
Intervention: Usual cardiac care
Number of subjects: 193
Study 17934162 — intervention group
Group type: COMPARATOR
Intervention: 0.4 mg ITM alone
Number of subjects: 80
Study 17934162 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 microg ITS plus 0.4 mg ITM
Number of subjects: 80
Study 15105028 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplement containing whey protein, amino acids, creatine, and carbohydrate
Number of subjects: 41
Study 15105028 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate-only control drink
Number of subjects: 41
Study 15105028 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplement
Number of subjects: 41
Study 15105028 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 41
Study 11665963 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline, 100 mg twice per day
Number of subjects: 60
Study 11665963 — intervention group
Group type: COMPARATOR
Intervention: Hydroxychloroquine, 200 mg twice per day
Number of subjects: 60
Study 11665963 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline
Number of subjects: 60
Study 11665963 — intervention group
Group type: COMPARATOR
Intervention: Hydroxychloroquine
Number of subjects: 60
Study 9440749 — intervention group
Group type: EXPERIMENTAL
Intervention: IVMTX 1,000 mg/m2 plus IVMP 1,000 mg/m2 (regimen A)
Number of subjects: 709
Study 9440749 — intervention group
Group type: COMPARATOR
Intervention: LDMTX 30 mg/m2 every 6 hours for six doses with IVMP 1,000 mg/m2 (regimen B)
Number of subjects: 709
Study 8089345 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral midazolam at a dose of 0.5 mg/kg with 25 mg hydroxyzine pamoate suspension as a vehicle
Number of subjects: 100
Study 8089345 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal midazolam at a dose of 0.2 mg/kg
Number of subjects: 100
Study 8089345 — intervention group
Group type: COMPARATOR
Intervention: Both oral and nasal midazolam
Number of subjects: 100
Study 2818919 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2.25 mg kg‐1
Number of subjects: 48
Study 2818919 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopentone 4.8 mg kg‐1
Number of subjects: 48
Study 2818919 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 1.8 mg kg‐1
Number of subjects: 48
Study 2818919 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopentone 4.7 mg kg‐1
Number of subjects: 48
Study 31754133 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone (CTD)
Number of subjects: 0
Study 31754133 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 0
Study 31754133 — intervention group
Group type: COMPARATOR
Intervention: β-blockers (metoprolol)
Number of subjects: 0
Study 31754133 — intervention group
Group type: COMPARATOR
Intervention: β-blockers (atenolol)
Number of subjects: 0
Study 28193104 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary training on spiritual care (SC) for nurses
Number of subjects: 255
Study 28193104 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary training on spiritual care (SC) for physicians
Number of subjects: 255
Study 27686138 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated Patients (SP) training
Number of subjects: 24
Study 27686138 — intervention group
Group type: COMPARATOR
Intervention: Seminar training
Number of subjects: 24
Study 25145487 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1,200 mg/day)
Number of subjects: 930
Study 22309819 — intervention group
Group type: EXPERIMENTAL
Intervention: Power of Two Online (self‐paced, Internet‐based marriage and relationship skills education program)
Number of subjects: 79
Study 22309819 — intervention group
Group type: COMPARATOR
Intervention: Placebo-control group
Number of subjects: 79
Study 20447955 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronan (sodium hyaluronate; Hyalgan) - 5 intra-articular injections weekly for 5 weeks
Number of subjects: 337
Study 20447955 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo) - 5 intra-articular injections weekly for 5 weeks
Number of subjects: 337
Study 20447955 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronan
Number of subjects: 337
Study 20447955 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 337
Study 20447955 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronan and Saline
Number of subjects: 337